[go: up one dir, main page]

WO2011030351A3 - Taste - masked pharmaceutical compositions - Google Patents

Taste - masked pharmaceutical compositions Download PDF

Info

Publication number
WO2011030351A3
WO2011030351A3 PCT/IN2010/000589 IN2010000589W WO2011030351A3 WO 2011030351 A3 WO2011030351 A3 WO 2011030351A3 IN 2010000589 W IN2010000589 W IN 2010000589W WO 2011030351 A3 WO2011030351 A3 WO 2011030351A3
Authority
WO
WIPO (PCT)
Prior art keywords
taste
tablets
pde
pharmaceutical compositions
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000589
Other languages
French (fr)
Other versions
WO2011030351A2 (en
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rubicon Research Pvt Ltd
Original Assignee
Rubicon Research Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Pvt Ltd filed Critical Rubicon Research Pvt Ltd
Publication of WO2011030351A2 publication Critical patent/WO2011030351A2/en
Publication of WO2011030351A3 publication Critical patent/WO2011030351A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to taste-masked pharmaceutical compositions comprising phosphodiesterase-5 (PDE-5) inhibitors. The taste-masked pharmaceutical compositions for oral administration comprise at least one PDE-5 inhibitor, at least one taste-masking agent; and at least one pharmaceutically acceptable excipient. Further the taste-masked PDE-5 inhibitor compositions are provided in the form of palatable formulations suitable for oral administration such as orally disintegrating tablets, bite-dispersion tablets, chewable tablets, dispersible tablets, effervescent tablets or the like. The invention also further relates to method for masking the objectionable taste of PDE-5 inhibitor.
PCT/IN2010/000589 2009-09-03 2010-09-03 Taste - masked pharmaceutical compositions Ceased WO2011030351A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2021/MUM/2009 2009-09-03
IN2021MU2009 2009-09-03

Publications (2)

Publication Number Publication Date
WO2011030351A2 WO2011030351A2 (en) 2011-03-17
WO2011030351A3 true WO2011030351A3 (en) 2011-06-30

Family

ID=43567799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000589 Ceased WO2011030351A2 (en) 2009-09-03 2010-09-03 Taste - masked pharmaceutical compositions

Country Status (1)

Country Link
WO (1) WO2011030351A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130058160A (en) * 2011-11-25 2013-06-04 한국유나이티드제약 주식회사 Chewable tablet of sildenafil citrate masked bitterness and method for making same
KR101960100B1 (en) * 2011-12-08 2019-03-19 에스케이케미칼 주식회사 Film for oral cavity administration containing mirodenafil or its pharmaceutically acceptable salt
MX366768B (en) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Orodispersible sildenafil tablet and preparation method thereof.
WO2014092661A1 (en) * 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2013109221A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic New effervescent formulations comprising sweetener composition
EP2641477B2 (en) 2012-03-19 2022-06-08 Symrise AG Compositions of matter
ES2674811T3 (en) * 2012-07-02 2018-07-04 Hetero Research Foundation Stable Fesoterodine Compositions
CN102727455B (en) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 A kind of tadalafil oral cavity disintegration tablet and preparation method thereof
CN102727456B (en) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 Drug port cavity disintegrating tablet and preparation method thereof
KR101953735B1 (en) * 2012-12-14 2019-03-04 한미약품 주식회사 Chewable tablet comprising a phosphodiesterase-5 inhibitor
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20160287656A1 (en) * 2013-03-20 2016-10-06 Natureceuticals Sdn Bhd Herbaceutical Formulations
CN104352461B (en) * 2013-04-28 2017-07-14 南京海融医药科技股份有限公司 The oral drug preparation of Tadalafei
CN103271885A (en) * 2013-05-23 2013-09-04 浙江华海药业股份有限公司 Tadalafil orally disintegrating tablet and preparation method thereof
EP3003285B1 (en) * 2013-06-03 2022-02-16 McNeil AB Solid pharmaceutical dosage form for release of at least two active pharmaceutical ingredients in the oral cavity
KR102239291B1 (en) * 2013-06-28 2021-04-14 한미약품 주식회사 Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof
CN104644574B (en) * 2013-11-18 2017-08-01 深圳海王医药科技研究院有限公司 A kind of sildenafil citrate taste masking preparation
US20160317542A1 (en) * 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
KR101485177B1 (en) * 2014-02-10 2015-01-23 한국유나이티드제약 주식회사 Bitterness-masked chewable tablet of sildenafil citrate and a method for making the same
CN105213333A (en) * 2014-06-30 2016-01-06 深圳海王药业有限公司 A kind of tadanafil pharmaceutical composition and preparation method thereof
KR101561406B1 (en) * 2015-02-02 2015-10-16 환인제약 주식회사 Solid dispersion containing dutasteride and composition containing the solid dispersion
BR112018000254A2 (en) 2015-07-07 2018-09-04 H Lundbeck As pde9 inhibitors with imidazotriazinone main chain and imidazopyrazinone main chain for the treatment of peripheral diseases
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler
CA3046025A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN107694476B (en) * 2017-07-25 2020-07-10 江苏远鸿新材料科技有限公司 Forming and manufacturing method of high-strength spherical drying agent
CA3079929A1 (en) * 2017-10-26 2019-05-02 Mw Encap Limited Liquid filled formulations of pde5 inhibitors
IT201800003507A1 (en) * 2018-03-13 2019-09-13 Fulton Medicinali S P A SUBLINGUAL TABLET INCLUDING SILDENAFIL CITRATE
BR112020024019A2 (en) 2018-05-25 2021-02-23 Imara Inc. monohydrate and crystalline forms of 6 - [(3s, 4s) -4-methyl-1- (pyrimidin-2-ylmethyl) pyrrolidin-3-yl] -3-tetrahydropyran-4-yl-7h-imidazo [1, 5-a] pyrazin-8-one
CA3110680A1 (en) * 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
CN111110683B (en) * 2018-10-31 2023-08-15 广东东阳光药业股份有限公司 A kind of solifenacin taste-masking composition and preparation method thereof
EP3956024A4 (en) * 2019-04-18 2023-01-11 Ellamed IP & Services Pte. Ltd. Liquid sildenafil citrate compositions
KR102249155B1 (en) * 2019-07-26 2021-05-07 주식회사 코아팜바이오 A pharmaceutical composition comprising udenafil
WO2022216294A1 (en) * 2021-04-09 2022-10-13 Auson Pharmaceuticals Inc. Powder for oral suspension containing tadalafil
CN114957332A (en) * 2022-05-30 2022-08-30 苏州正永生物医药有限公司 Avanafil phosphate compound and preparation method and application thereof
IT202200016533A1 (en) * 2022-08-03 2024-02-03 Recordati Ind Chimica E Farmaceutica S P A INNOVATIVE COMPLEXION OF THE LIPID-STEROLIC EXTRACT OF SERENOA WITH TADALAFIL.
WO2024158694A1 (en) * 2023-01-23 2024-08-02 Villya LLC Compositions and methods for improving the solubility of erectile dysfunction therapeutics
EP4655005A1 (en) * 2023-01-27 2025-12-03 Bayer HealthCare LLC Taste-masking with a multi-component physical barrier
CN115990140A (en) * 2023-02-15 2023-04-21 北京悦康科创医药科技股份有限公司 Nafil compound freeze-dried tablet and preparation method thereof
CN117243927A (en) * 2023-10-17 2023-12-19 深圳市泰力生物医药有限公司 Caliperazine hydrochloride oral soluble film preparation containing safe and effective taste masking agent and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017976A1 (en) * 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited, Fast dissolving and taste masked oral dosage form comprising sildenafil
WO2004087111A1 (en) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Oral taste masked pharmaceutical compositions
WO2006047493A2 (en) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2009074995A1 (en) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Taste masked chewable compositions of sildenafil citrate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900061A (en) 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
CA2379948C (en) 1999-08-03 2008-03-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
WO2006091974A1 (en) 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Tadalafil having a large particle size and a process for preparation thereof
MX2008000087A (en) 2005-06-23 2008-03-18 Schering Corp Rapidly absorbing oral formulations of pde5 inhibitors.
PT1843770E (en) 2005-08-29 2008-08-05 Teva Pharma Solid particulate tadalafil having a bimodal particle size distribution
EP1937217A2 (en) 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoparticulate tadalafil formulations
BRPI0709909A2 (en) 2006-03-31 2011-07-26 Rubicon Res Private Ltd oral disintegration tablets
RU2009103660A (en) 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) SOLID PHARMACEUTICAL COMPOSITIONS, INCLUDING TADALAFIL AND AT LEAST ONE CARRIER

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017976A1 (en) * 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited, Fast dissolving and taste masked oral dosage form comprising sildenafil
WO2004087111A1 (en) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Oral taste masked pharmaceutical compositions
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2006047493A2 (en) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105039A1 (en) * 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2009074995A1 (en) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Taste masked chewable compositions of sildenafil citrate

Also Published As

Publication number Publication date
WO2011030351A2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
WO2011030351A3 (en) Taste - masked pharmaceutical compositions
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
MX2008000087A (en) Rapidly absorbing oral formulations of pde5 inhibitors.
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2007100614A3 (en) STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2009084017A3 (en) Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
WO2008038003A3 (en) Pharmaceutical compositions of aripiprazole
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
SG166115A1 (en) Pharmaceutical preparation containing meloxicam
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
MX2009007784A (en) Compositions of stable tiacumicins.
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
MX2016014771A (en) Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use.
WO2008035380A3 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2010127100A8 (en) Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
WO2008081268A3 (en) Pharmaceutical compositions of entacapone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10803268

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10803268

Country of ref document: EP

Kind code of ref document: A2